Wegovy vs Saxenda
Peptide Schedule Research TeamReviewed Apr 202615 Citations
Wegovy (semaglutide 2.4 mg weekly) and Saxenda (liraglutide 3.0 mg daily) are both FDA-approved GLP-1 receptor agonists for chronic weight management. Wegovy produces roughly double the weight loss but Saxenda now has a generic option at lower cost.
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix.
View full guide →The LEADER trial enrolled 9,340 people with type 2 diabetes and high cardiovascular risk. After a median follow-up of 3.8 years, liraglutide cut major adverse cardiovascular events by 13% (HR 0.87, 95% CI 0.78 to 0.97, PMID 27295427). That result changed how doctors thought about GLP-1 receptor agonists. Liraglutide (also sold as Victoza for diabetes and Saxenda for weight management) is a modified version of human GLP-1 with 97% amino acid homology to the native hormone. A palmitic acid chain at position 26 lets it bind albumin in the blood. That binding shields it from DPP-IV breakdown and extends the half-life from about 2 minutes to roughly 13 hours, long enough for once-daily dosing. On the weight side, the SCALE Obesity and Prediabetes trial (n=3,731, PMID 25673007) showed 8.0% mean body weight loss at 56 weeks on the 3 mg dose versus 2.6% on placebo. A head-to-head comparison in STEP 8 (PMC8753508) put those numbers in context: semaglutide 2.4 mg weekly produced 15.8% loss versus 6.4% for liraglutide 3 mg daily over 68 weeks. The practical picture for most users looks like this: a pre-filled pen (no mixing needed), weekly dose increases from 0.6 mg up to 3.0 mg, and GI side effects that peak during titration but usually settle within a few weeks. Appetite suppression kicks in within days of the first injection. Teva's generic launched in August 2025, bringing costs down from brand Saxenda pricing (~$1,300 to $1,800 per month) to roughly $1,165 per month, with compounded options running $150 to $249.
View full guide →At a Glance
| Attribute |   Semaglutide |   Liraglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | B | A |
| Half-Life | ~7 days | ~13 hours |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5mg, 10mg | 18mg |
| Beginner Dose | 250mcg Weekly | 600mcg Daily |
| Moderate Dose | 500mcg Weekly | 1800mcg Daily |
| Aggressive Dose | 1000mcg Weekly | 3000mcg Daily |
| Dosing Source | FDA Label | FDA Label |
| Side Effects | Black box warning: semaglutide causes thyroid C-cell tumors in rodents. Whether it causes medullary thyroid carcinoma in humans is unknown. Anyone with a personal or family history of MTC or MEN2 cannot use this drug. That warning is printed on every Wegovy and Ozempic label, and it stays there. GI side effects dominate the titration period. Nausea hits 40 to 50% of patients during the first weeks at each new dose level. For some, that nausea is severe enough to impact daily function and work productivity. Community consensus recommends extending each titration step to 6 to 8 weeks rather than 4 if nausea is bad. The nausea typically fades within the first week at each stable dose. Constipation affects the majority of long-term users. Proactive fiber supplementation (psyllium husk from day one) is the top community recommendation. Magnesium citrate at 200 to 400 mg before bed serves as the standard backup. Vomiting and diarrhea also occur, usually transiently during dose escalation. Rare but serious: pancreatitis requires immediate emergency evaluation if you experience severe abdominal pain radiating to the back. Gallbladder disease (cholelithiasis, cholecystitis) is a known complication, particularly with rapid weight loss. Acute kidney injury can result from dehydration driven by persistent GI symptoms. FDA postmarketing warnings from September 2023 flagged three additional signals. Ileus (intestinal obstruction) requires emergency care if you develop severe persistent abdominal pain. Diabetic retinopathy complications can paradoxically worsen with rapid A1c improvement in patients with pre-existing retinopathy. Resting heart rate increases a mean 1 to 4 bpm; 26% of SELECT participants had increases of 20 bpm or more. The 7.2 mg Wegovy HD dose introduced a new signal: dysesthesia (tingling, numbness) in 18.9% of patients vs. 0% on placebo in STEP UP. That adverse event profile is still being characterized. Hair thinning from telogen effluvium peaks between months 3 and 6. It is a response to rapid weight loss, not a direct drug effect. It typically resolves by month 8 to 12 with adequate protein intake. Lean mass loss of 25 to 40% of total weight lost is documented without resistance training. "Ozempic face" (facial volume loss) becomes visible after 30+ lbs of weight loss. Contraindications: personal or family history of MTC or MEN2, history of pancreatitis, pregnancy or breastfeeding, hypersensitivity to semaglutide, severe gastrointestinal disease including gastroparesis. If you are on insulin or sulfonylureas, doses of those drugs typically need a 20 to 30% reduction at semaglutide initiation to prevent hypoglycemia. | Liraglutide carries a black box warning for medullary thyroid carcinoma. In rodent studies, liraglutide caused dose-dependent thyroid C-cell tumors at exposures 8 times the human dose. No confirmed human cases appeared in the LEADER trial (0 MTC in the liraglutide arm versus 1 in placebo, n=9,340). Still, the warning makes liraglutide off-limits for anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). GI side effects are the most common reason people quit. Nausea hits roughly 40% of users at the 3 mg dose. Vomiting, diarrhea, and constipation affect 15 to 20%. The pattern is predictable: symptoms peak during each dose increase and fade over 2 to 3 weeks at a stable dose. Slow titration (advancing by 0.6 mg per week as labeled) reduces the severity. Some community users extend to 2 weeks per step if nausea is severe. Pancreatitis occurs in under 0.4% of patients. The LEADER trial found rates similar to placebo, but the risk is real. Severe abdominal pain radiating to the back, with or without vomiting, means stop the drug and get evaluated immediately. Gallbladder disease showed up in about 2.2% of SCALE trial participants. GLP-1 receptor agonists slow gallbladder emptying, and rapid weight loss adds to gallstone risk. Right upper quadrant pain warrants an ultrasound. LEADER turned up a slight numerical imbalance in total malignancies (10.1% liraglutide versus 9.0% placebo, HR approximately 1.06). This was not statistically significant. The clinical meaning is unclear, but it was observed and should be noted. Hypoglycemia is rare when liraglutide is used alone. It becomes a genuine risk when combined with insulin or sulfonylureas; dose reductions of those medications are often needed. Injection site reactions are mild and infrequent. Hair thinning (telogen effluvium) shows up in community reports. This is driven by rapid weight loss rather than a direct drug effect. It's typically self-limiting. When to seek medical attention: severe abdominal pain, persistent vomiting, signs of allergic reaction, or any visual changes. Stop liraglutide at least 2 months before planned conception; the drug was detected in milk of lactating rats, and human data on infant risk are insufficient. |
Key Differences
- Wegovy is once-weekly injection. Saxenda is once-daily. For most patients, weekly dosing means better adherence and fewer missed doses.
- STEP 1 showed 14.9% mean weight loss with Wegovy at 68 weeks. SCALE showed 8.0% with Saxenda at 56 weeks. Wegovy consistently outperforms Saxenda in clinical trials.
- Saxenda has the generic advantage. Teva's generic liraglutide launched August 2025, and compounded liraglutide starts at about $150 per month. Generic semaglutide is still years away (earliest estimates 2028 to 2030).
- Wegovy now has an oral tablet (approved December 2025) starting at $149 per month through the NovoCare program. This eliminates the injection barrier entirely.
- Both carry the same black box warning for thyroid C-cell tumors based on rodent data. The GI side effect profile is similar, with nausea affecting 39% on Wegovy vs 40% on Saxenda during titration.
When to Choose Wegovy
- Maximum weight loss is the goal (14.9% vs 8.0% in trials)
- Once-weekly dosing for convenience and adherence
- Cardiovascular risk reduction matters (SELECT trial, n=17,604)
- You want the oral tablet option ($149/month, no injections)
When to Choose Saxenda
- Cost is the deciding factor (generic liraglutide available, compounded from $150/month)
- You prefer daily dosing for more precise dose adjustments
- You've tried semaglutide and had intolerable side effects
- Your insurance covers Saxenda but not Wegovy
Can You Stack Wegovy + Saxenda?
Wegovy and Saxenda both target the GLP-1 receptor. Taking both would double GLP-1 stimulation, causing severe nausea, vomiting, and potentially dangerous GI side effects. Choose one or the other.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Frequently Asked Questions
Not medical advice. Talk to your provider before using any peptide.
Full disclaimer